TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF GLOBAL SUBMENTAL FAT TREATMENT MARKET 23
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 24
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.6 MULTIVARIATE MODELLING 34
2.7 TYPE LIFELINE CURVE 34
2.8 DBMR MARKET POSITION GRID 35
2.9 MARKET APPLICATION COVERAGE GRID 37
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 INDUSTRY INSIGHTS 44
4.1 REIMBURSEMENT SCENARIO 44
5 MARKET OVERVIEW 45
5.1 DRIVERS 47
5.1.1 INCREASING AWARENESS FOR COSMETIC PROCEDURES AMONG PEOPLE 47
5.1.2 RISING PREVALENCE OF OBESITY 47
5.1.3 INCREASING DEMAND FOR MINIMALLY INVASIVE PROCEDURES 48
5.1.4 INCREASED RELIABILITY ON LIPOSUCTION PROCEDURE 49
5.1.5 AVAILABILITY OF ADVANCED AND USER FRIENDLY PRODUCTS 49
5.2 RESTRAINTS 50
5.2.1 HIGH COST OF PROCEDURES 50
5.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 50
5.2.3 STRINGENT REGULATIONS FOR APPROVAL OF PRODUCTS 51
?
5.3 OPPORTUNITIES 52
5.3.1 EVOLUTION IN LASER AND RF DEVICES 52
5.3.2 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR COSMETIC PROCEDURES 53
5.3.3 INTRODUCTION OF NOVEL NON- INVASIVE TECHNOLOGY 53
5.4 CHALLENGES 54
5.4.1 INCREASED RECOVERY TIME OF PROCEDURES 54
5.4.2 REQUIREMENT OF MULTIPLE SESSIONS FOR GETTING MAXIMUM RESULTS 54
6 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY TYPE 55
6.1 OVERVIEW 56
6.2 MINIMALLY INVASIVE & NON-INVASIVE TECHNOLOGY 59
6.2.1 ULTRASOUND 59
6.2.2 CRYOLIPOLYSIS 60
6.2.3 RADIOFREQUENCY-ASSISTED CONTOURING 60
6.2.4 LOW-LEVEL LASERS 60
6.2.5 COMBINATION TREATMENT 60
6.2.6 INJECTABLE ADIPOCYTOLYSIS 60
6.2.7 OTHERS 60
6.3 INVASIVE METHOD 61
6.3.1 LIPOSUCTION 61
6.3.2 SURGICAL REJUVENATION 61
6.3.3 CHIN IMPLANT 61
7 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY END USER 62
7.1 OVERVIEW 63
7.2 COSMETIC CENTERS 66
7.3 HOSPITALS 66
7.4 DERMATOLOGY CLINICS 67
7.5 MEDICAL SPA 67
7.6 OTHERS 68
8 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY DISTRIBUTION CHANNEL 69
8.1 OVERVIEW 70
8.2 DIRECT TENDER 73
8.3 RETAIL SALES 73
9 GLOBAL SUBMENTAL FAT TREATMENT MARKET, BY GEOGRAPHY 74
9.1 OVERVIEW 75
9.2 NORTH AMERICA 80
9.2.1 U.S. 85
9.2.2 CANADA 87
9.2.3 MEXICO 89
9.3 EUROPE 91
9.3.1 GERMANY 96
9.3.2 FRANCE 98
9.3.3 ITALY 100
9.3.4 U.K. 102
9.3.5 SPAIN 104
9.3.6 RUSSIA 106
9.3.7 NETHERLANDS 108
9.3.8 SWITZERLAND 110
9.3.9 BELGIUM 112
9.3.10 TURKEY 114
9.3.11 REST OF EUROPE 116
9.4 ASIA-PACIFIC 117
9.4.1 JAPAN 122
9.4.2 CHINA 124
9.4.3 AUSTRALIA 126
9.4.4 SOUTH KOREA 128
9.4.5 SINGAPORE 130
9.4.6 INDIA 132
9.4.7 MALAYSIA 134
9.4.8 THAILAND 136
9.4.9 INDONESIA 138
9.4.10 PHILIPPINES 140
9.4.11 REST OF ASIA-PACIFIC 142
9.5 SOUTH AMERICA 143
9.5.1 BRAZIL 148
9.5.2 ARGENTINA 150
9.5.3 REST OF SOUTH AMERICA 152
9.6 MIDDLE EAST & AFRICA 153
9.6.1 SAUDI ARABIA 158
9.6.2 SOUTH AFRICA 160
9.6.3 U.A.E. 162
9.6.4 ISRAEL 164
9.6.5 EGYPT 166
9.6.6 REST OF MIDDLE EAST & AFRICA 168
10 GLOBAL SUBMENTAL FAT TREATMENT MARKET, COMPANY LANDSCAPE 169
10.1 COMPANY SHARE ANALYSIS: GLOBAL 169
10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 170
10.3 COMPANY SHARE ANALYSIS: EUROPE 171
10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 172
11 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS 173
11.1 SWOT ANALYSIS 173
11.1.1 STRENGTH: - SIGNIFICANT GROWTH OF SHARES IN MARKET FOCUSED SEGMENT 173
11.1.2 STRENGTH: - FOCUSED ON AESTHETIC SOLUTIONS 173
11.1.3 WEAKNESS: DEPENDENCE ON SUPPLIERS/ DISTRIBUTORS 174
11.1.4 OPPORTUNITY: - STRATEGIC INITIATIVES FOR BUSINESS EXPANISION BY PRODUCT LAUNCH, ACQUISITION AND OTHERS 174
11.1.5 THREAT: - CURRENCY FLUCTUATION 175
11.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 175
12 COMPANY PROFILE 176
12.1 ALLERGAN 176
12.1.1 COMPANY SNAPSHOT 176
12.1.2 REVENUE ANALYSIS 177
12.1.3 COMPANY SHARE ANALYSIS 177
12.1.4 PRODUCT PORTFOLIO 178
12.1.5 RECENT DEVELOPMENTS 178
12.2 INMODE 179
12.2.1 COMPANY SNAPSHOT 179
12.2.2 REVENUE ANALYSIS 180
12.2.3 COMPANY SHARE ANALYSIS 180
12.2.4 PRODUCT PORTFOLIO 181
12.2.5 RECENT DEVELOPMENT 181
12.3 HIRONIC CO., LTD. 182
12.3.1 COMPANY SNAPSHOT 182
12.3.2 REVENUE ANALYSIS 182
12.3.3 COMPANY SHARE ANALYSIS 183
12.3.4 PRODUCT PORTFOLIO 183
12.3.5 RECENT DEVELOPMENT 183
12.4 CANDELA CORPORATION 184
12.4.1 COMPANY SNAPSHOT 184
12.4.2 COMPANY SHARE ANALYSIS 184
12.4.3 PRODUCT PORTFOLIO 185
12.4.4 RECENT DEVELOPMENT 185
12.5 CYNOSURE LLC 186
12.5.1 COMPANY SNAPSHOT 186
12.5.2 PRODUCT PORTFOLIO 186
12.5.3 RECENT DEVELOPMENTS 186
?
12.6 BTL GROUP OF COMPANIES 187
12.6.1 COMPANY SNAPSHOT 187
12.6.2 SOLUTION PORTFOLIO 187
12.6.3 RECENT DEVELOPMENTS 187
12.7 ALMA LASERS (A SUBSIDIARY OF SISRAM MEDICAL LTD) 188
12.7.1 COMPANY SNAPSHOT 188
12.7.2 REVENUE ANALYSIS 188
12.7.3 PRODUCT PORTFOLIO 189
12.7.4 RECENT DEVELOPMENTS 189
12.8 ENDYMED MEDICAL 190
12.8.1 COMPANY SNAPSHOT 190
12.8.2 REVENUE ANALYSIS 190
12.8.3 PRODUCT PORTFOLIO 191
12.8.4 RECENT DEVELOPMENT 191
12.9 CUTERA 192
12.9.1 COMPANY SNAPSHOT 192
12.9.2 REVENUE ANALYSIS 193
12.9.3 PRODUCT PORTFOLIO 193
12.9.4 RECENT DEVELOPMENT 193
12.10 ALASTIN SKINCARE, INC. 194
12.10.1 COMPANY SNAPSHOT 194
12.10.2 PRODUCT PORTFOLIO 194
12.10.3 RECENT DEVELOPMENTS 194
12.11 ERCHONIA CORPORATION 195
12.11.1 COMPANY SNAPSHOT 195
12.11.2 PRODUCT PORTFOLIO 195
12.11.3 RECENT DEVELOPMENT 195
12.12 LASER LIPO LTD. 196
12.12.1 COMPANY SNAPSHOT 196
12.12.2 PRODUCT PORTFOLIO 196
12.12.3 RECENT DEVELOPMENT 196
12.13 LUMENIS 197
12.13.1 COMPANY SNAPSHOT 197
12.13.2 PRODUCT PORTFOLIO 197
12.13.3 RECENT DEVELOPMENT 197
12.14 SOLTA MEDICAL 198
12.14.1 COMPANY SNAPSHOT 198
12.14.2 BRAND PORTFOLIO 198
12.14.3 RECENT DEVELOPMENT 198
?
12.15 THERMIGEN, LLC. 199
12.15.1 COMPANY SNAPSHOT 199
12.15.2 PRODUCT PORTFOLIO 199
12.15.3 RECENT DEVELOPMENT 199
13 QUESTIONNAIRE 200
14 CONCLUSION 202
15 RELATED REPORTS 203